MSB 4.07% $1.15 mesoblast limited

The investment case FOR Mesoblast, page-17

  1. 400 Posts.
    lightbulb Created with Sketch. 57
    Yes, of course have a balanced opinion. Whole world is aware of Stemcells and their relevance in future. MSB has been in the ditches since a very long time to bring theory into practice.

    Yes, the new lifeline of $110 million is a celebration moment for MSB.

    But now MSB need to deliver on at least ONE of their products I.e. FDA Approval. Just ONE to remain relevant.

    Additionally, for science there should be no budget limitations but for Administrative and Office expenditure there should be a set budget and it should be way below the current expenditure. CEO should manage the costs and be held responsible. We are not here to fund a lifestyle. And if can’t, then better concentrate on the science and hire someone with Health industry Business Acumen and respect this person’s hard business decisions to cut gross expenses.

    Finally, the ridiculously high salaries and remuneration packages of the management is contrary to the wealth generation prospects of shareholders.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.15
Change
0.045(4.07%)
Mkt cap ! $1.313B
Open High Low Value Volume
$1.08 $1.16 $1.08 $4.681M 4.170M

Buyers (Bids)

No. Vol. Price($)
1 99680 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 31000 2
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.